Skip to content

TScan Therapeutics, Inc.

Public company
Headquarters
WALTHAM, Massachusetts
Industry
Biotechnology
Ticker
TCRX
CIK
0001783328

WARN notices since 2024

1
First: Sep 2, 2026

Workers affected since 2024

96
Across 1 notice

Executive changes, last 12 months

7
3 appointments, 4 departures

Last event

Oct 16, 2026
Executive departureDirector departs: Garry Nicholson

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
DirectorGarry NicholsonOct 16, 2026Departed
memberStephen BiggarOct 16, 2026Appointed
chairpersonR. Keith WoodsOct 16, 2026Appointed
CFOJason A. AmelloSep 2, 2026Departed
CMOChrystal Louis, M.D., MPHSep 2, 2026Departed
CEOGavin MacBeath, Ph.D.Sep 2, 2026Appointed

Related companies

Same industry and state, with recent events.

  1. Executive departure

    Director departs: Garry Nicholson

    Garry Nicholson, Director of TScan Therapeutics, Inc., resigns the role, effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Director

    Source: SEC 8-K, filed Oct 16, 2026

  2. Executive departure

    Director departs: Gabriela Gruia, M.D.

    Gabriela Gruia, M.D., Director of TScan Therapeutics, Inc., resigns the role, effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Director

    Source: SEC 8-K, filed Oct 16, 2026

  3. Executive appointment

    member appointed: Stephen Biggar

    Stephen Biggar was named member of TScan Therapeutics, Inc., effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: member

    Source: SEC 8-K, filed Oct 16, 2026

  4. Executive appointment

    chairperson appointed: R. Keith Woods

    R. Keith Woods was named chairperson of TScan Therapeutics, Inc., effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: chairperson

    Source: SEC 8-K, filed Oct 16, 2026

  5. Executive departure

    CFO departs: Jason A. Amello

    Jason A. Amello, Chief Financial Officer of TScan Therapeutics, Inc., leaves the role, effective September 2, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Financial Officer

    Source: SEC 8-K, filed Sep 2, 2026

  6. Executive departure

    CMO departs: Chrystal Louis, M.D., MPH

    Chrystal Louis, M.D., MPH, Chief Medical Officer of TScan Therapeutics, Inc., leaves the role, effective September 2, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Medical Officer

    Source: SEC 8-K, filed Sep 2, 2026

  7. Executive appointment

    CEO appointed: Gavin MacBeath, Ph.D.

    Gavin MacBeath, Ph.D. was named Chief Executive Officer of TScan Therapeutics, Inc., effective September 2, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Executive Officer

    Source: SEC 8-K, filed Sep 2, 2026

Last verified Nov 8, 2026